MW 696.7 Da, Purity >98%. Amyloid fibril-binding dye. Caspase inhibitor. Red shifts on aggregation and binding to amyloid fibrils. Blue shifts on binding to cellulose. Shows apple green birefringence under polarized light in the presence of amyloid fibrils. Inhibits Fib-beta A neurotoxicity.
A BETA, A4 amyloid protein, A4_HUMAN, AAA, ABPP, AD1, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), APP, APPI, ATX, ATX X, Acetyl CoA choline O acetyltransferase, Acetyl CoA:choline O acetyltransferase, Alzheimer disease amyloid protein, Amyloid beta (A4) precursor protein, Amyloid beta A4 protein, Amyloid beta protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, Amyloid precursor protein, Autotaxin, Autotaxin t, Beta-APP40, Beta-APP42, Beta-amyloid precursor protein, C31, CHOACTase, CLAT_HUMAN, CMS1A, CMS1A2, CTFgamma, CVAP, Cerebral vascular amyloid peptide, ChAT, Choline O acetyltransferase, Choline acetylase, DHFR, DHFRP1, DYR_HUMAN, Dihydrofolate reductase, EC 1.5.1.3, EC 2.3.1.6, ENPP2_HUMAN, Ectonucleotide pyrophosphatase/phosphodiesterase 2, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2, Extracellular lysophospholipase D, FLJ26803, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), LysoPLD, NPP2, OTTHUMP00000019583, OTTHUMP00000019584, PD IALPHA, PDNP2, PN 2, PN-II, Phosphodiesterase I alpha, Phosphodiesterase I/nucleotide pyrophosphatase 2, Plasma lysophospholipase D, PreA4, Protease nexin-II, S-APP-alpha, S-APP-beta, beta-amyloid peptide, choline acetyltransferase, peptidase nexin-II, sAPP
MW 696.7 Da, Purity >98%. Amyloid fibril-binding dye. Caspase inhibitor. Red shifts on aggregation and binding to amyloid fibrils. Blue shifts on binding to cellulose. Shows apple green birefringence under polarized light in the presence of amyloid fibrils. Inhibits Fib-beta A neurotoxicity.
Soluble in water to 5 mM.
Soluble in DMSO to 5 mM.
Amyloid fibril-binding dye. Caspase inhibitor. Red shifts on aggregation and binding to amyloid fibrils. Blue shifts on binding to cellulose. Shows apple green birefringence under polarized light in the presence of amyloid fibrils. Inhibits Fib-beta A neurotoxicity.
This product is manufactured by BioVision, an Abcam company and was previously called 2588 Congo Red. 2588-500 is the same size as the 500 mg size of ab145645.
Choline acetyltransferase (ChAT) amyloid precursor protein (APP) and dihydrofolate reductase (DHFR) are important biological targets expressing distinct mechanical functions. ChAT is an enzyme that synthesizes the neurotransmitter acetylcholine; it is mainly expressed in the central and peripheral nervous systems. ChAT has a mass of about 69 kDa and alternative names include CAT or CHAT. The amyloid precursor protein (APP) is a transmembrane protein with a role in synaptic formation and repair and weighs approximately 100-140 kDa depending on its isoform. It is abundantly expressed in neurons. Dihydrofolate reductase (DHFR) is an important enzyme in folate metabolism vital for DNA synthesis and exists in many tissues especially in the liver. ENPP2 also known as autotaxin (ATX) is an enzyme involved in lysophospholipid metabolism with wide expression in various tissues.
The synthesis of acetylcholine by ChAT is essential for cholinergic neurotransmission influencing muscle activation and several aspects of cognition. ChAT doesn't function as part of a complex acting independently to catalyze the conversion of acetyl-CoA and choline into acetylcholine. In contrast APP undergoes proteolytic processing leading to the formation of amyloid-beta associated with amyloid plaque formation in Alzheimer's disease. DHFR plays an integral role in the reduction of dihydrofolate to tetrahydrofolate critical for synthesizing nucleotides for DNA replication. ENPP2/ATX generates lysophosphatidic acid (LPA) which modulates cell proliferation and migration.
ChAT is pivotal in the acetylcholine biosynthesis pathway interacting with other enzymes involved in neurotransmitter cycling such as acetylcholinesterase which breaks down acetylcholine. APP is central to the amyloidogenic and non-amyloidogenic pathways which include secretase-mediated cleavage that can also involve presenilin enzymes. DHFR is part of the folate pathway essential for the de novo synthesis of purine and thymidylate and shares involvement with the enzyme thymidylate synthase. ENPP2/ATX has significant roles in the LPA signaling pathway interacting with LPA receptors which activate various downstream signaling cascades.
Alterations in ChAT are associated with neurodegenerative diseases such as Alzheimer's where acetylcholine levels are critically reduced. In Alzheimer's disease APP through its cleavage products also plays an important pathogenic role associated with amyloid plaque formation. Meanwhile DHFR is a target in cancer treatment strategies where antifolate drugs aim to halt cancer cell proliferation by inhibiting folate metabolism. ENPP2/ATX links to several conditions including cancer metastasis and fibrosis related to its role in activating LPA signaling that influences cancer cell behavior.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab145645, Congo Red, Amyloid fibril-binding dye
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com